ISSN: 1309 - 3843 E-ISSN: 1307 - 7384
FİZİKSEL TIP VE REHABİLİTASYON
BİLİMLERİ DERGİSİ
www.jpmrs.com
Kayıtlı İndexler


OLGU SUNUMLARI

COVID-19 Sonrası Lupus-Pernio-Benzeri Sendromlu Bir Olgu Sunumu
A Case Report with Post COVID-19 Lupus-Pernio-Like Syndrome
Received Date : 05 Jan 2022
Accepted Date : 21 Apr 2022
Available Online : 06 May 2022
Doi: 10.31609/jpmrs.2022-88007 - Makale Dili: EN
J PMR Sci. 2023;26(1):103-7
ÖZET
Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)], çeşitli diğer virüslerde gördüğümüz gibi çeşitli otoimmün hastalıkları tetikleyebilir. Bunlara örnek olarak Guillain-Barré sendromu, Bell paralizi, Miller Fisher sendromu ve hastalığa bağlı viral artrit verilebilir. COVID-19 pandemisi tüm dünyada hızla ilerlerken bu alandaki literatür bilgimiz de hızla artıyor. Burada COVID-19 sonrası lupus-pernio-benzeri sendrom tanısı konan 30 yaşında bir kadın hastayı sunuyoruz. Hasta, sağ ayak bileğinde şişlik ve sıcaklık, sağ elin 5. parmağında (küçük parmak) ağrı ve şişlik şikâyetleri ile tarafımıza başvurdu. Öz geçmişinde 2 ay önce COVID-19 olduğu öğrenildi. Hasta nonsteroid antiinflamatuar tedaviden fayda görmedi. Güncel literatürde COVID-19 sonrası ilişkili lupus-pernio-benzeri sendromu olan birkaç olgu bildirilmiştir.
ABSTRACT
Coronavirus disease-2019 (COVID-19) can trigger a variety of autoimmune diseases, as we have seen with a variety of other viruses. Examples of these are Guillain-Barré syndrome, Bell's palsy, Miller Fisher syndrome and viral arthritis related to the disease. The COVID-19 pandemic is progressing rapidly all over the world, our literature knowledge in this field is rapidly increasing. Here, we present a 30-year-old female patient diagnosed with Post COVID-19 lupuspernio- like syndrome. The patient presented to us with the complaints of swelling and warmth in the right ankle and pain and swelling in the 5th finger (little finger) of the right hand. In her history, it was learned that she had COVID-19 2 months ago. The patient did not benefit from the non-steroidal anti-inflammatory treatment. A few cases with post- COVID-19 associated lupus-pernio-like syndrome have been reported in the current literature.
REFERENCES
  1. Wollina U, Karadağ AS, Rowland-Payne C, et al. Cutaneous signs in COVID-19 patients: a review. Dermatol Ther. 2020;33:e13549. [Crossref]  [PubMed]  [PMC] 
  2. Gisondi P, PIaserico S, Bordin C, Alaibac M, Girolomoni G, Naldi L. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2499-2504. [Crossref]  [PubMed]  [PMC] 
  3. Kocyigit BF, Akyol A. Reactive arthritis after COVID-19: a case-based review. Rheumatol Int. 2021;41:2031-9. [Crossref]  [PubMed]  [PMC] 
  4. Gül Ü. COVID-19 and dermatology. Turk J Med Sci. 2020;50:1751-9. [Crossref]  [PubMed]  [PMC] 
  5. Dobesh PP, Trujillo TC. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19. Pharmacotherapy. 2020 Nov;40(11):1130-1151. [Crossref]  [PubMed]  [PMC] 
  6. Gavriilaki E, Anyfanti P, Gavriilaki M, et al. Endothelial dysfunction in COVID-19: lessons learned from coronaviruses. Curr Hypertens Rep. 2020;22:63. [Crossref]  [PubMed]  [PMC] 
  7. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382:e38. [Crossref]  [PubMed]  [PMC] 
  8. Harzallah I, Debliquis A, Drénou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost. 2020;18:2064-5. [Crossref]  [PubMed]  [PMC] 
  9. Derksen RH, de Groot PG. Clinical consequences of antiphospholipid antibodies. Neth J Med. 2004;62:273-8. [PubMed] 
  10. Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost. 2020:10.1111/jth.14893. [Crossref]  [PubMed]  [PMC] 
  11. Zuo Y, Estes SK, Ali RA, et al. Prothrombotic antiphospholipid antibodies in COVID-19. medRxiv [Preprint]. 2020:2020.06.15.20131607. [Crossref]  [PubMed]  [PMC] 
  12. Devreese KMJ, Linskens EA, Benoit D, et al. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020;18:2191-201. [Crossref]  [PubMed]  [PMC] 
  13. Askanase AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. Lupus Sci Med. 2020;7:e000396. [Crossref]  [PubMed]  [PMC] 
  14. El Aoud S, Morin C, Lorriaux P, et al. COVID-19 presenting as lupus erythematosus-like syndrome. Disaster Med Public Health Prep. 2021;15:e12-e15. [Crossref]  [PubMed]  [PMC] 
  15. Yasri S, Wiwanitkit V. Systemic lupus erythematosus, varicella-like rash, and COVID-19. J Med Virol. 2021;93:1212. [Crossref]  [PubMed]  [PMC] 
  16. Shayestehpour M, Zamani B. Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient. J Med Virol. 2021;93:2599. [Crossref]  [PubMed]  [PMC] 
  17. Battesti G, El Khalifa J, Abdelhedi N, et al. New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus. J Am Acad Dermatol. 2020;83:1219-22. [Crossref]  [PubMed]  [PMC]